Emerging biology of pde10a

Current Pharmaceutical Design

Volumn 21, Issue 3, 2015, Pages 378-388

  Wilson, Lindsay S ^a   Brandon, Nicholas J ^b  

^a PFIZER INC   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Cyclic AMP; Cyclic GMP; Genetics; Phosphodiesterase 10A (PDE10A)

Indexed keywords

CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; UNCLASSIFIED DRUG; PDE10A PROTEIN, HUMAN; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; AUTISM; BASAL GANGLION; BIPOLAR DISORDER; CELLULAR DISTRIBUTION; CONNECTOME; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; NERVE CELL DIFFERENTIATION; NEURODEVELOPMENTAL DISEASE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BRAIN DISEASES; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; ENZYMOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

BRAIN DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 84925872454     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140826114744     Document Type: Article

References (137)

1. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011; 91: 651-90.
2. Xu Y, Zhang HT, O'Donnell JM. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handb Exp Pharmacol 2011: 447-85.
3. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
4. Edwards HV, Christian F, Baillie GS. cAMP: novel concepts in compartmentalised signalling. Semin Cell Dev Biol 2012; 23: 181-90.
5. Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 2010; 35: 91-100.
6. Siuciak JA. The role of phosphodiesterases in schizophrenia : therapeutic implications. CNS Drugs 2008; 22: 983-93.
7. Rizzo SJ, Edgerton JR, Hughes ZA, Brandon NJ. Future viable models of psychiatry drug discovery in pharma. J Biomol Screen 2013; 18: 509-21.
8. Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem 2009; 52: 5188-96.
9. DeMartinis N, Banerjee A, Kumar V, Boyer S, Schmidt C, Arroyo S. Results of a Phase 2A Proof-of-Concept Trial with a PDE10A Inhibitor in the Treatment of Acute Exacerbation of Schizophrenia. Schizophrenia Research-Supplemental 2012; 136: Poster 212.
10. Siuciak JA, Chapin DS, Harms JF, et al. Inhibition of the striatumenriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006; 51: 386-96.
11. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007; 8: 54-9.
12. Kehler J, Nielsen J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 2011; 17: 137-50.
13. Fujishige K, Kotera J, Omori K. Striatum-and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 1999; 266: 1118-27.
14. Kotera J, Fujishige K, Yuasa K, Omori K. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem Biophys Res Commun 1999; 261: 551-7.
15. Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 1999; 96: 7071-6.
16. Coskran TM, Morton D, Menniti FS, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006; 54: 1205-13.
17. Fujishige K, Kotera J, Michibata H, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999; 274: 18438-45.
18. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA. Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. Gene 1999; 234: 109-17.
19. Seeger TF, Bartlett B, Coskran TM, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003; 985: 113-26.
20. Xie Z, Adamowicz WO, Eldred WD, et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 2006; 139: 597-607.
21. Charych EI, Jiang LX, Lo F, Sullivan K, Brandon NJ. Interplay of palmitoylation and phosphorylation in the trafficking and localization of phosphodiesterase 10A: implications for the treatment of schizophrenia. J Neurosci 2010; 30: 9027-37.
22. Kennedy MJ, Davison IG, Robinson CG, Ehlers MD. Syntaxin-4 defines a domain for activity-dependent exocytosis in dendritic spines. Cell 2010; 141: 524-35.
23. Kennedy MJ, Ehlers MD. Mechanisms and function of dendritic exocytosis. Neuron 2011; 69: 856-75.
24. Lu J, Helton TD, Blanpied TA, Racz B, Newpher TM, Weinberg RJ, et al. Postsynaptic positioning of endocytic zones and AMPA receptor cycling by physical coupling of dynamin-3 to Homer. Neuron 2007; 55: 874-89.
25. Petrini EM, Lu J, Cognet L, Lounis B, Ehlers MD, Choquet D. Endocytic trafficking and recycling maintain a pool of mobile surface AMPA receptors required for synaptic potentiation. Neuron 2009; 63: 92-105.
26. Kotera J, Sasaki T, Kobayashi T, Fujishige K, Yamashita Y, Omori K. Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMPdependent protein kinase-dependent phosphorylation. J Biol Chem 2004; 279: 4366-75.
27. Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006; 51: 374-85.
28. Dlaboga D, Hajjhussein H, O'Donnell JM. Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B,-4B, and-10A expression in rat striatum. Neuropharmacology 2008; 54: 745-54.
29. Haber SN, Rauch SL. Neurocircuitry: a window into the networks underlying neuropsychiatric disease. Neuropsychopharmacology 2010; 35: 1-3.
30. Surmeier DJ, Carrillo-Reid L, Bargas J. Dopaminergic modulation of striatal neurons, circuits, and assemblies. Neuroscience 2011; 198: 3-18.
31. Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 2011; 34: 441-66.
32. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007; 30: 228-35.
33. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, Jr., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-32.
34. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR. Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation. J Pharmacol Exp Ther 2009; 328: 785-95.
35. Choi YS, Lee B, Cho HY, et al. CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease. Neurobiol Dis 2009; 36: 259-68.
36. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
37. DeMarch Z, Giampa C, Patassini S, Bernardi G, Fusco FR. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2008; 30: 375-87.
38. Goedert, M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9: 13-24.
39. Strakowski, SM, Delbello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry 2005; 10: 105-16.
40. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993; 72: 971-83.
41. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 2013; 28: 14-23.
42. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-75.
43. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. Trends Neurosci 1995; 18: 11-4.
44. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995; 11: 155-63.
45. Albin RL. Selective neurodegeneration in Huntington's disease. Ann Neurol 1995; 38: 835-6.
46. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985; 227: 770-3.
47. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-77.
48. Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992; 31: 425-30.
49. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-81.
50. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986; 321: 168-71.
51. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
52. Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004; 123: 967-81.
53. Li JY, Popovic N, Brundin P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005; 2: 447-64.
54. DeMarch Z, Giampa C, Patassini S, Martorana A, Bernardi G, Fusco FR. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol Dis 2007; 25: 266-73.
55. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008; 325: 681-90.
56. Giampa C, Patassini S, Borreca A, et al. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol Dis 2009; 34: 450-6.
57. Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 2010; 5: e13417.
58. Leuti A, Laurenti D, Giampa C, et al. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2013; 52: 104-16.
59. Giralt A, Saavedra A, Carreton O, et al. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a huntington's disease mouse model. Hippocampus 2013: 0.
60. Kleiman RJ, Kimmel LH, Bove SE, et al. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease. J Pharmacol Exp Ther 2011; 336: 64-76.
61. Roze E, Betuing S, Deyts C, et al. Mitogen-and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtininduced transcriptional dysregulation and striatal death. FASEB J 2008; 22: 1083-93.
62. Martin E, Betuing S, Pages C, et al. Mitogen-and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter. Hum Mol Genet 2011; 20: 2422-34.
63. Breedveld GJ, Percy AK, MacDonald ME, et al. Clinical and genetic heterogeneity in benign hereditary chorea. Neurology 2002; 59: 579-84.
64. Breedveld GJ, van Dongen JW, Danesino C, et al. Mutations in TITF-1 are associated with benign hereditary chorea. Hum Mol Genet 2002; 11: 971-9.
65. Devos D, Vuillaume I, de Becdelievre A, et al. New syndromic form of benign hereditary chorea is associated with a deletion of TITF-1 and PAX-9 contiguous genes. Mov Disord 2006; 21: 2237-40.
66. Mahajnah M, Inbar D, Steinmetz A, Heutink P, Breedveld GJ, Straussberg R. Benign hereditary chorea: clinical, neuroimaging, and genetic findings. J Child Neurol 2007; 22: 1231-4.
67. Kaye JA, Finkbeiner S. Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci 2013; 56C: 50-64.
68. Carri AD, Onorati M, Lelos MJ, et al. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 2013; 140: 301-12.
69. Niclis JC, Pinar A, Haynes JM, et al. Characterization of forebrain neurons derived from late-onset Huntington's disease human embryonic stem cell lines. Front Cell Neurosci 2013; 7: 37.
70. Hornykiewicz O. Parkinson's disease and its chemotherapy. Biochem Pharmacol 1975; 24: 1061-5.
71. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010; 6: 702-6.
72. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 2013; 20: 16-34.
73. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010; 6: 309-17.
74. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58.
75. Cheshire PA, Williams DR. Serotonergic involvement in levodopainduced dyskinesias in Parkinson's disease. J Clin Neurosci 2012; 19: 343-8.
76. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1: 292-6.
77. Calabresi P, Di Filippo M, Gallina A, et al. New synaptic and molecular targets for neuroprotection in Parkinson's disease. Mov Disord 2013; 28: 51-60.
78. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 1995; 18: 527-35.
79. Calabresi P, Gubellini P, Centonze D, et al. A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci 1999; 19: 2489-99.
80. Del Bel EA, Guimaraes FS, Bermudez-Echeverry M, et al. Role of nitric oxide on motor behavior. Cell Mol Neurobiol 2005; 25: 371-92.
81. Sammut S, Park DJ, West AR. Frontal cortical afferents facilitate striatal nitric oxide transmission in vivo via a NMDA receptor and neuronal NOS-dependent mechanism. J Neurochem 2007; 103: 1145-56.
82. Giorgi M, D'Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, et al. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 2008; 28: 941-50.
83. Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci USA 2005; 102: 1199-204.
84. West AR, Grace AA. The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity States and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J Neurosci 2004; 24: 1924-35.
85. Eve DJ, Nisbet AP, Kingsbury AE, et al. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain Res Mol Brain Res 1998; 63: 62-71.
86. Bockelmann R, Wolf G, Ransmayr G, Riederer P. NADPHdiaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J Neural Transm Park Dis Dement Sect 1994; 7: 115-21.
87. Hossain MA, Weiner N. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. J Pharmacol Exp Ther 1993; 267: 1105-11.
88. Tenn CC, Niles LP. Sensitization of G protein-coupled benzodiazepine receptors in the striatum of 6-hydroxydopaminelesioned rats. J Neurochem 1997; 69: 1920-6.
89. Sancesario G, Giorgi M, D'Angelo V, Modica A, Martorana A, Morello M, et al. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci 2004; 20: 989-1000.
90. Chalimoniuk M, Langfort J. The effect of subchronic, intermittent L-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice. Neurochem Int 2007; 50: 821-33.
91. Chalimoniuk M, Langfort J, Lukacova N, Marsala J. Upregulation of guanylyl cyclase expression and activity in striatum of MPTPinduced parkinsonism in mice. Biochem Biophys Res Commun 2004; 324: 118-26.
92. Tseng KY, Caballero A, Dec A, et al. Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism. PLoS One 2011; 6: e27187.
93. Guigoni C, Dovero S, Aubert I, et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 2005; 22: 283-7.
94. Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006; 5: 845-54.
95. Winkler C, Kirik D, Bjorklund A, Cenci MA. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002; 10: 165-86.
96. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005; 57: 17-26.
97. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopainduced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001; 2: 577-88.
98. Santini E, Valjent E, Usiello A, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 2007; 27: 6995-7005.
99. Park DJ, Campbell PW, Mudrakola V, et al. Inhibition of phosphodiesterase 10A modulates levodopa-induced dyskinesias in parkinsonian rats. Society for Neuroscience Abstracts 2011; 37.
100. [100] Cooper O, Seo H, Andrabi S, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012; 4: 141ra90.
101. [101] Liu GH, Qu J, Suzuki K, et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012; 491: 603-7.
102. [102] Reinhardt P, Schmid B, Burbulla LF, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013; 12: 354-67.
103. [103] Imaizumi Y, Okada Y, Akamatsu W, et al. Mitochondrial dysfunction associated with increased oxidative stress and alphasynuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 2012; 5: 35.
104. [104] Mantamadiotis T, Lemberger T, Bleckmann SC, et al. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 2002; 31: 47-54.
105. [105] Sakamoto K, Karelina K, Obrietan K. CREB: a multifaceted regulator of neuronal plasticity and protection. J Neurochem 2011; 116: 1-9.
106. [106] Mironov SL, Skorova EY, Kugler S. Epac-mediated cAMPsignalling in the mouse model of Rett Syndrome. Neuropharmacology 2011; 60: 869-77.
107. [107] Kelley DJ, Davidson RJ, Elliott JL, Lahvis GP, Yin JC, Bhattacharyya A. The cyclic AMP cascade is altered in the fragile X nervous system. PLoS One 2007; 2: e931.
108. [108] Penze, P, Woolfrey KM, Srivastava DP. Epac2-mediated dendritic spine remodeling: implications for disease. Mol Cell Neurosci 2011; 46: 368-80.
109. [109] Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 2011; 14: 285-93.
110. [110] Brandon NJ, Millar JK, Korth C, Sive H, Singh KK, Sawa A. Understanding the role of DISC1 in psychiatric disease and during normal development. J Neurosci 2009; 29: 12768-75.
111. [111] Kamiya A, Kubo K, Tomoda T, et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol 2005; 7: 1167-78.
112. [112] Singh KK, Ge X, Mao Y, et al. Dixdc1 is a critical regulator of DISC1 and embryonic cortical development. Neuron 2010; 67: 33-48.
113. [113] McQueen MB, Devlin B, Faraone SV, et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet 2005; 77: 582-95.
114. [114] McDonald ML, MacMullen C, Liu DJ, Leal SM, Davis RL. Genetic association of cyclic AMP signaling genes with bipolar disorder. Transl Psychiatry 2012; 2: e169.
115. [115] Marshall CR, Noor A, Vincent JB, et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008; 82: 477-88.
116. [116] Ravel C, Berthaut I, Bresson JL, Siffroi JP, Genetics Commission of the French Federation of C. Prevalence of chromosomal abnormalities in phenotypically normal and fertile adult males: large-scale survey of over 10, 000 sperm donor karyotypes. Hum Reprod 2006; 21: 1484-9.
117. [117] Talkowski ME, Rosenfeld JA, Blumenthal I, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 2012; 149: 525-37.
118. [118] American Psychiatric Association. Diagnostic criteria from DSMIV-TR. Washington, D.C.: American Psychiatric Association; 2000. xii, 370 p. p.
119. [119] Chang A, Li PP, Warsh JJ. Altered cAMP-dependent protein kinase subunit immunolabeling in post-mortem brain from patients with bipolar affective disorder. J Neurochem 2003; 84: 781-91.
120. [120] Fields A, Li PP, Kish SJ, Warsh JJ. Increased cyclic AMPdependent protein kinase activity in postmortem brain from patients with bipolar affective disorder. J Neurochem 1999; 73: 1704-10.
121. [121] Perez J, Tardito D, Racagni G, Smeraldi E, Zanardi R. cAMP signaling pathway in depressed patients with psychotic features. Mol Psychiatry 2002; 7: 208-12.
122. [122] Tardito D, Mori S, Racagni G, Smeraldi E, Zanardi R, Perez J. Protein kinase A activity in platelets from patients with bipolar disorder. J Affect Disord 2003; 76: 249-53.
123. [123] Ebstein RP, Lerer B, Shapira B, Shemesh Z, Moscovich DG, Kindler S. Cyclic AMP second-messenger signal amplification in depression. Br J Psychiatry 1988; 152: 665-9.
124. [124] Extein I, Tallman J, Smith CC, Goodwin FK. Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Res 1979; 1: 191-7.
125. [125] Masana MI, Bitran JA, Hsiao JK, Mefford IN, Potter WZ. Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study. Brain Res 1991; 538: 333-6.
126. [126] Montezinho LP, Mork A, Duarte CB, Penschuck S, Geraldes CF, Castro MM. Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D(2)-like receptors. Bipolar Disord 2007; 9: 290-7.
127. [127] Mork A, Geisler A, Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol 1992; 71 Suppl 1: 4-17.
128. [128] Risby ED, Hsiao JK, Manji HK, et al. The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and betaadrenergic receptor binding in normal subjects. Arch Gen Psychiatry 1991; 48: 513-24.
129. [129] Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience 2009; 164: 331-43.
130. [130] Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 2003; 123C: 48-58.
131. [131] Green EK, Hamshere M, Forty L, et al. Replication of bipolar disorder susceptibility alleles and identification of two novel genome-wide significant associations in a new bipolar disorder case-control sample. Mol Psychiatry 2012.
132. [132] Delmonte S, Gallagher L, O'Hanlon E, McGrath J, Balsters JH. Functional and structural connectivity of frontostriatal circuitry in Autism Spectrum Disorder. Front Hum Neurosci 2013; 7: 430.
133. [133] Dichter GS. Functional magnetic resonance imaging of autism spectrum disorders. Dialogues Clin Neurosci 2012; 14: 319-51.
134. [134] Hallahan BP, Craig MC, Toal F, et al. In vivo brain anatomy of adult males with Fragile X syndrome: an MRI study. Neuroimage 2011; 54: 16-24.
135. [135] Jung KM, Sepers M, Henstridge CM, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 2012; 3: 1080.
136. [136] Geschwind DH. Autism: many genes, common pathways? Cell 2008; 135: 391-5.
137. [137] Murdoch JD, State MW. Recent developments in the genetics of autism spectrum disorders. Curr Opin Genet Dev 2013.